BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 326665)

  • 1. Capsule size of Cryptococcus neoformans: control and relationship to virulence.
    Dykstra MA; Friedman L; Murphy JW
    Infect Immun; 1977 Apr; 16(1):129-35. PubMed ID: 326665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans.
    Kwon-Chung KJ; Rhodes JC
    Infect Immun; 1986 Jan; 51(1):218-23. PubMed ID: 3079732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virulence, capsule size and lipid composition interrelation of Cryptococcus neoformans.
    Upreti HB; Rawat DS; Das SK
    Microbiologica; 1984 Oct; 7(4):371-4. PubMed ID: 6392831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.
    Granger DL; Perfect JR; Durack DT
    J Clin Invest; 1985 Aug; 76(2):508-16. PubMed ID: 3928681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.
    Fromtling RA; Shadomy HJ; Jacobson ES
    Mycopathologia; 1982 Jul; 79(1):23-9. PubMed ID: 6750405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Buoyancy of
    Vij R; Cordero RJB; Casadevall A
    mSphere; 2018 Nov; 3(6):. PubMed ID: 30404928
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of pathogenic constituents of Cryptococcus neoformans strains.
    Kagaya K; Yamada T; Miyakawa Y; Fukazawa Y; Saito S
    Microbiol Immunol; 1985; 29(6):517-32. PubMed ID: 3900645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic and virulence factors analyses of Cryptococcus neoformans hypoxia response.
    Kong Q; Yang R; Wang Z; Zhou W; Du X; Huang S; Jiang Y; Liu W; Sang H
    APMIS; 2017 Mar; 125(3):236-248. PubMed ID: 28233445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virulence and antifungal susceptibility of environmental and clinical isolates of Cryptococcus neoformans from Puerto Rico.
    Fromtling RA; Abruzzo GK; Ruiz A
    Mycopathologia; 1989 Jun; 106(3):163-6. PubMed ID: 2682249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic activity of a clinical isolate of Cryptococcus neoformans.
    Brueske CH
    J Clin Microbiol; 1986 Mar; 23(3):631-3. PubMed ID: 3514663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors.
    Clancy CJ; Nguyen MH; Alandoerffer R; Cheng S; Iczkowski K; Richardson M; Graybill JR
    Microbiology (Reading); 2006 Aug; 152(Pt 8):2247-2255. PubMed ID: 16849791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hypertonic solutes upon the polysaccharide capsule in Cryptococcus neoformans.
    Jacobson ES; Tingler MJ; Quynn PL
    Mycoses; 1989 Jan; 32(1):14-23. PubMed ID: 2664504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phospholipase activity in Cryptococcus neoformans: a new virulence factor?
    Chen SC; Muller M; Zhou JZ; Wright LC; Sorrell TC
    J Infect Dis; 1997 Feb; 175(2):414-20. PubMed ID: 9203663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aging: an emergent phenotypic trait that contributes to the virulence of Cryptococcus neoformans.
    Bouklas T; Fries BC
    Future Microbiol; 2015; 10(2):191-7. PubMed ID: 25689531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Carbon Dioxide Concentration Is an Independent Stress for Cryptococcus neoformans That Affects Virulence and Antifungal Susceptibility.
    Krysan DJ; Zhai B; Beattie SR; Misel KM; Wellington M; Lin X
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryptococcus neoformans: pseudohyphal forms surviving culture with Acanthamoeba polyphaga.
    Neilson JB; Ivey MH; Bulmer GS
    Infect Immun; 1978 Apr; 20(1):262-6. PubMed ID: 352931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptococcus neoformans: size range of infectious particles from aerosolized soil.
    Neilson JB; Fromtling RA; Bulmer GS
    Infect Immun; 1977 Sep; 17(3):634-8. PubMed ID: 332630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans.
    Rhodes JC; Polacheck I; Kwon-Chung KJ
    Infect Immun; 1982 Jun; 36(3):1175-84. PubMed ID: 6807845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization and evaluation of virulence factors of Cryptococcus laurentii and Cryptococcus neoformans strains isolated from external hospital areas.
    Andrade-Silva L; Ferreira-Paim K; Silva-Vergara ML; Pedrosa AL
    Fungal Biol; 2010; 114(5-6):438-45. PubMed ID: 20943154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Culture of Cryptococcus neoformans in the nonencapsulated state.
    Tripp C; Ruiz A; Bulmer GS
    Mycopathologia; 1981 Dec; 76(3):129-31. PubMed ID: 7033796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.